We are developing our pipeline of cell therapy products basing on two novel patient blood cell-independent platform technologies to manufacture “off-the-shelf” cell-based cancer immunotherapies, namely CAR-γδ T cell technology (CTM-N2D therapy) and iPSC-derived γδ NKT cell technology (gdNKT therapy). Both types of therapies exploit the multiple antigen recognition systems of natural killer (NK) cells and γδ T cells and may be used to recognize and treat a broad range of cancers. We expect to expand our pipeline further in phase II trials of CTM-N2D therapy for specific cancer indications.
Comparing with autologous γδ T cells expanded from patient’s own blood cells, allogeneic γδ T cells expanded from blood cells of healthy donors may provide a more potent cytotoxic cell source. Moreover, unlike autologous γδ T cells, the number of allogeneic γδ T cells that can be obtained during manufacturing is not restricted by the starting materials. Hence, it is valuable to further explore the potency of allogeneic γδ T cells in clinical trials. To this end, we are also developing allogeneic γδ T cells into CTM-GDT therapy for cancer treatment